NCT00397891 - Study Evaluating Single Ascending Doses of AAB-001 Vaccine SAD Japanese Patients With Alzheimers Disease | Biotech Hunter

Enrollment

80

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

February 28, 2010

Study Completion Date

February 28, 2010

Conditions

Alzheimer Disease

Interventions

DRUG

bapineuzumab

The dose cohorts are as follows: 0.15 mg/kg AAB-001; 0.5 mg/kg AAB-001; 1.0 mg/kg AAB-001. Placebo is vehicle (all ingredients except active). In each dose cohort, designated as groups 1 to 3, study drug (AAB-001 or placebo) will be administered as an intravenous infusion over 1 hour.

DRUG

bapineuzumab

The dose cohorts are as follows: 0.15 mg/kg AAB-001; 0.5 mg/kg AAB-001; 1.0 mg/kg AAB-001. Placebo is vehicle (all ingredients except active). In each dose cohort, designated as groups 1 to 3, study drug (AAB-001 or placebo) will be administered as an intravenous infusion over 1 hour.

DRUG

bapineuzumab

The dose cohorts are as follows: 0.15 mg/kg AAB-001; 0.5 mg/kg AAB-001; 1.0 mg/kg AAB-001. Placebo is vehicle (all ingredients except active). In each dose cohort, designated as groups 1 to 3, study drug (AAB-001 or placebo) will be administered as an intravenous infusion over 1 hour.

Trial Locations (4)

Unknown

Pfizer Investigational Site, Chiba

Pfizer Investigational Site, Saitama

Pfizer Investigational Site, Shizuoka

Pfizer Investigational Site, Tokyo